Drugs that contain Cabazitaxel
1. Jevtana Kit patents expiration
JEVTANA KIT's oppositions filed in EPO
JEVTANA KIT Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6331635 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2016
(8 years ago) | |
| US5847170 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2021
(3 years ago) | |
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
| US6372780 | SANOFI AVENTIS US | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar, 2016
(8 years ago) | |
| US6387946 | SANOFI AVENTIS US | Methods for treating pathological conditions of abnormal cell proliferation |
Mar, 2016
(8 years ago) | |
|
US5847170 (Pediatric) | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep, 2021
(2 years ago) | |
|
US7241907 (Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(2 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
|
US8927592 (Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-209) | Sep 14, 2020 |
| M(M-201) | May 17, 2020 |
| M(M-128) | Dec 18, 2023 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: Treatment of cancer; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlo...
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage
JEVTANA KIT family patents
